NCT05522491 2025-12-11
Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer
Hebei Medical University Fourth Hospital
Phase 2 Not yet recruiting
Hebei Medical University Fourth Hospital
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
InxMed (Shanghai) Co., Ltd.
Qilu Pharmaceutical Co., Ltd.
Zhengzhou Revo-Gene Technology Co., LTD
Binhui Biopharmaceutical Co., Ltd.
European Institute of Oncology
Qingdao Sino-Cell Biomedicine Co., Ltd.
Beidahuang Industry Group General Hospital
Nuwacell Biotechnologies Co., Ltd.
Suzhou BlueHorse Therapeutics Co., Ltd.
Suzhou BlueHorse Therapeutics Co., Ltd.